Literature DB >> 21962892

Molecular characterization of an EWSR1-POU5F1 fusion associated with a t(6;22) in an undifferentiated soft tissue sarcoma.

Fang-Ming Deng1, Karen Galvan, Gustavo de la Roza, Shengle Zhang, Abdul-Kader Souid, Constance K Stein.   

Abstract

We report a soft tissue sarcoma from the thigh with morphologic features resembling Ewing sarcoma, clear cell sarcoma, and myoepithelial tumor of soft tissue. In addition, the genetic and immunohistochemical findings do not correspond to any established pattern, so the tumor does not clearly fit into any one classification. The karyotype analysis revealed a rare chromosomal rearrangement, t(6;22)(p22;q12), that previously has been reported in bone and epithelial tumors. Molecular studies confirmed the presence of an EWSR1-POU5F1 fusion creating a chimeric gene with the N-terminal transcriptional activation domain of EWSR1 and the C-terminal POU DNA binding domain of POU5F1. This report is novel in that to our knowledge, it is the first complete molecular characterization of an EWSR1-POU5F1 fusion in a soft tissue sarcoma. Evaluation of existing data on the known EWSR1-POU5F1 tumors suggests that the fusion gene functions in a wide variety of cell types and may modify the differentiation state of cells, resulting in susceptibility to tumorigenesis.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21962892     DOI: 10.1016/j.cancergen.2011.05.006

Source DB:  PubMed          Journal:  Cancer Genet


  2 in total

1.  Rhabdoid Variant of Myoepithelial Carcinoma, with EWSR1 Rearrangement: Expanding the Spectrum of EWSR1-Rearranged Myoepithelial Tumors.

Authors:  Khin Thway; Nick Bown; Aisha Miah; Rob Turner; Cyril Fisher
Journal:  Head Neck Pathol       Date:  2014-07-04

2.  Pluripotency Stemness and Cancer: More Questions than Answers.

Authors:  Jiří Hatina; Michaela Kripnerová; Zbyněk Houdek; Martin Pešta; Filip Tichánek
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.